Neuropsychology of Financial Capacity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

99 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-04

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present project aims to investigate the financial capacity in patients diagnosed with Parkinson's Disease or parkinsonism, brain tumor (glioma or meningioma) and cerebrovascular lesion (stroke), in order to evaluate the presence and degree of impairment, and the role of some factors as potential predictors of financial incapacity.

The term 'financial capacity' means both operations relating, for example, to asset management or investing money, and activities of daily life such as shopping or using small sums of money; these activities are mediated by different cognitive functions, from numerical and arithmetic skills to decision making. Financial capacity is, in fact, an instrumental activity of daily life (i.e. Instrumental Activity Of Daily Living, I-ADL) whose impairment negatively affects the functional autonomy of the individual, so as to be subject to legal protection.

To assess financial capacity, the Numerical Activities of Daily Living - Financial (NADL-F; Arcara et al., 2017) will be administered, a battery of tests aimed at investigating both financial performance and financial competence according to the most recent neuropsychological models proposed in the literature.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Free-living Monitoring of Parkinson's Disease Using Smart Objects

NCT05830253

Parkinson Disease

COMPLETED

Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD

NCT07187843

Parkinson Disease Parkinsonian Disorders Brain Disease +2 more

RECRUITING

Instrumental Assessment of Motor Symptoms by Means of Wearable Sensors in Patients With Parkinson's Disease

NCT05349539

Parkinson Disease Motor Disorders

UNKNOWN

Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation

NCT03336307

Parkinson Disease Movement Disorders

COMPLETED

Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease

NCT01113242

Parkinson Disease Dementia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Brain Tumor Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Parkinson's Disease/Parkinsonisms

Neuropsychological tests

Intervention Type BEHAVIORAL

Neuropsychological assessment with:

* NADL-F
* Frontal Assessment Battery (FAB)
* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

Patients with brain tumors

Neuropsychological tests

Intervention Type BEHAVIORAL

Neuropsychological assessment with:

* NADL-F
* Frontal Assessment Battery (FAB)
* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

Patients with ischemic or haemorrhagic stroke

Neuropsychological tests

Intervention Type BEHAVIORAL

Neuropsychological assessment with:

* NADL-F
* Frontal Assessment Battery (FAB)
* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

Healthy Controls

Neuropsychological tests

Intervention Type BEHAVIORAL

Neuropsychological assessment with:

* NADL-F
* Frontal Assessment Battery (FAB)
* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuropsychological tests

Neuropsychological assessment with:

* NADL-F
* Frontal Assessment Battery (FAB)
* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* Clinical diagnosis of interest for clinical groups
* For stroke patients: disease duration \> 1 month

Exclusion Criteria

* Other brain disorders different from those of interest
* Sensory-motor deficits that could prevent neuropsychological assessment
* Language disorders that could prevent neuropsychological assessment
* Global cognitive impairment as indexed by MoCA \< 26 or MMP \< 22.85

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes